RecruitingPhase 3NCT06664775

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

An Open Label, Prospective, Randomized, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of TachoSil® Versus Surgicel™ Original (Oxidized Regenerated Cellulose) as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery.


Sponsor

Corza Medical GmbH

Enrollment

116 participants

Start Date

Apr 2, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this clinical study is to assess the efficacy and safety of TachoSil compared to the widely known and used for \> 60 years local hemostatic product Surgicel Original as an adjunct to control mild to moderate soft tissue bleeding during surgery.


Eligibility

Min Age: 1 Month

Inclusion Criteria5

  • Elective open abdominal, retroperitoneal, pelvic, or thoracic surgery. Elective transplant surgery except for liver or heart transplants is included.
  • The participant has a need for secondary hemostatic study intervention at the TBS with mild to moderate bleeding Grade 1 and Grade 2 according to the VIBe Scale.
  • Presence of an appropriate mild to moderate bleeding soft tissue TBS identified intra-operatively by the surgeon.
  • The TBS size \< 21 cm2/3.3 in2.
  • Ability to firmly press study intervention at TBS until 3 minutes after randomization.

Exclusion Criteria10

  • Participants undergoing cardiovascular, hepatic, and laparoscopic and robotic surgeries.
  • Congenital or acquired disorders of coagulation.
  • Diseases requiring constant use of any anticoagulant drugs that cannot be safely washed out prior to randomization.
  • Screening Hemoglobin \< 9 mg/dL, platelets \< 75 × 103/µL, and/or international normalized ratio (INR) \> 1.5.
  • Acute major bleeding during surgery.
  • Participant with TBS in an actively infected field.
  • Target bleeding site is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency.
  • Target bleeding site with major arterial bleeding requiring suture or mechanical ligation.
  • Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine.
  • Participants with Grade '0', '3', and '4' bleeding at TBS according to VIBe Scale.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALTachoSil

Adjunct to hemostasis

BIOLOGICALSurgicel Original

Adjunct to hemostasis


Locations(9)

Torrance Memorial

Torrance, California, United States

St. Anthony Hospital

Lakewood, Colorado, United States

Georgetown University

Washington D.C., District of Columbia, United States

University Of Chicago

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

University of Louisville

Louisville, Kentucky, United States

Washington University

St Louis, Missouri, United States

Atrium Health Carolinas Medical Center

Charlotte, North Carolina, United States

The Ohio State University Medical Center

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06664775


Related Trials